Latest Novavax News & Updates

See the latest news and media coverage for Novavax. We track all announcements, press releases, and industry mentions in real time, all in one place.

Novavax

Biotechnology company developing vaccines

novavax.com

Headquarters: Gaithersburg, United States
Founded year: 1987
Company type: Public company
Number of employees: 900–1,000

Last updated Today

Latest news about Novavax

In short: Novavax reported stronger-than-expected Q1 2026 earnings as it pivoted from vaccine sales toward high-value technology licensing agreements.

Company announcements

May 6 Novavax

Novavax shares Q1 2026 financial results

They highlight progress on corporate growth strategy and invite to a live call at 8:30 a.m. ET.

May 6 Novavax

Novavax reports Q1 2026 financial results

Total revenue is $140 million. Announces Pfizer Matrix-M license and multiple MTAs. Reiterates 2026 revenue framework of $230-270 million.

April 30 Novavax

Novavax publishes Matrix-M safety data review

Interview with Jonathan Fix summarizes safety from 66 trials, showing mild reactogenicity and positive benefit-risk profile across populations.

April 29 Novavax

Novavax reports Q1 2026 financial results Wednesday

They share key operational highlights. Registration is available.

Media coverage

June 11 Yahoo Finance

Novavax Pivots To Matrix M Licensing As Sanofi Takes Europe

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or...

June 9 MSN

Novavax set for a seventh straight decline

Shares of Novavax (NVAX) fell 2.84% to $8.38 in the afternoon trade on Tuesday, adding to a six-session slide. The stock has fallen around 18...

June 3 Pharmaphorum

FDA finally okays Novavax's COVID-19 jab, with restrictions

The FDA has granted full approval to Novavax's COVID-19 vaccine after a delay, but has limited its use to older adults and people aged 12...

June 2 MSN

NVAX stock eyes breakout week: Novavax claims patients were 'twice as likely' to pick its COVID shot over Moderna again

・Novavax posted Q1 revenue of $139.5 million, above analysts' estimate of $78.3 million, helped by licensing agreements. ・The drugmaker also said that patients who received...

Never miss news about Novavax

Track Novavax and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Novavax competitors & trending companies

Browse news for competitors to Novavax and other trending companies.